Azenta, Inc. (NASDAQ:AZTA) specializes in providing life sciences solutions, focusing on sample management and genomic services. On November 21, 2025, Azenta reported its earnings, revealing an earnings per share (EPS) of $0.21, which matched the estimated EPS. The company achieved a revenue of approximately $159.2 million, surpassing the estimated revenue of about $156.4 million.
For the fourth quarter ending September 30, 2025, Azenta reported a 6% increase in revenue year-over-year, with a 4% growth on an organic basis. This growth contributed to a 4% revenue increase for the full fiscal year 2025, with a 3% organic rise. The company also expanded its adjusted EBITDA margin by 310 basis points compared to the previous year, indicating improved profitability.
Looking ahead to fiscal year 2026, Azenta anticipates organic revenue growth between 3% and 5%, along with an adjusted EBITDA margin expansion of approximately 300 basis points. John Marotta, President and CEO, described fiscal 2025 as transformative, highlighting the 3% core revenue growth and significant margin expansion. The Azenta Business System has played a key role in enhancing quality, delivery, and productivity.
Azenta maintains a strong liquidity position with a current ratio of approximately 2.96. This suggests the company has nearly three times more current assets than current liabilities, indicating financial stability. The debt-to-equity ratio of about 0.03 reflects a low level of debt relative to equity, further supporting its solid financial standing.
Azenta's enterprise value to sales ratio is approximately 2.12, reflecting the company's valuation relative to its revenue. The enterprise value to operating cash flow ratio is around 15.03, indicating how many times the operating cash flow can cover the enterprise value. Azenta expects to generate higher free cash flow in the coming year, signaling potential for future growth.
